These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 22801850)
1. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity. Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850 [No Abstract] [Full Text] [Related]
2. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity. Erol N; Gürsoy H; Sahin A; Basmak H J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371 [TBL] [Abstract][Full Text] [Related]
4. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183 [No Abstract] [Full Text] [Related]
5. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis. Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024 [TBL] [Abstract][Full Text] [Related]
6. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity. Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Moran S; O'Keefe M; Hartnett C; Lanigan B; Murphy J; Donoghue V Acta Ophthalmol; 2014 Sep; 92(6):e496-7. PubMed ID: 24428792 [No Abstract] [Full Text] [Related]
8. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab. Tseng CC; Chen SN; Hwang JF; Lin CJ J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829 [TBL] [Abstract][Full Text] [Related]
9. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Kim J; Kim SJ; Chang YS; Park WS Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184 [TBL] [Abstract][Full Text] [Related]
10. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118 [No Abstract] [Full Text] [Related]
11. Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity. Connor AJ; Papastavrou VT; Hillier RJ; Shafiq A J Pediatr Ophthalmol Strabismus; 2015 Apr; 52 Online():e20-1. PubMed ID: 25942065 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Refractive Errors and Ocular Biometric Outcomes after Intravitreal Bevacizumab for Retinopathy of Prematurity. Gunay M; Sekeroglu MA; Bardak H; Celik G; Esenulku CM; Hekimoglu E; Bardak Y Strabismus; 2016 Jun; 24(2):84-8. PubMed ID: 27120579 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026 [TBL] [Abstract][Full Text] [Related]
14. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Park SW; Jung HH; Heo H Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062 [No Abstract] [Full Text] [Related]
15. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435 [TBL] [Abstract][Full Text] [Related]
16. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Dorta P; Kychenthal A Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475 [TBL] [Abstract][Full Text] [Related]
17. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434 [TBL] [Abstract][Full Text] [Related]
18. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP). Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628 [No Abstract] [Full Text] [Related]
19. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity. Cheng HC; Lee SM; Hsieh YT; Lin PK Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709 [TBL] [Abstract][Full Text] [Related]